Stockreport

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update [Yahoo! Finance]

Rani Therapeutics Holdings, Inc. - Class A  (RANI) 
PDF - Announced new preclinical pharmacokinetic data supporting transenteric delivery of GLP-1 incretin triagonist - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual [Read more]